BERKELEY - BriaCell Therapeutics Corp. ('BriaCell' or the 'Company') (TSX-V: BCT) (OTCQB: BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce the presentation results of the clinical studies with its lead product candidate, Bria-IMT, summarized in a poster session held on December 9 - 11 during the 2020 San Antonio Breast Cancer Symposium (SABCS).

The poster summarizes the clinical and pathological data of the Bria-IMT monotherapy (i.e. the Bria-IMT regimen alone) study and Phase I/IIa clinical study of Bria-IMT in combination with immune checkpoint inhibitors including pembrolizumab (KEYTRUDA; manufactured by Merck & Co., Inc.), and more recently, Incyte's INCMGA00012 (by Incyte Corporation), in advanced breast cancer.

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

Cautionary Note Regarding Forward-Looking Information

Except for the statements of historical fact, this news release contains 'forward-looking information' within the meaning of the applicable Canadian securities legislation (also known as 'forward-looking statements') which are subject to known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at www.sedar.com.

These forward-looking statements include, but are not limited to, BriaCell's plans, objectives, expectations and intentions. Such forward-looking statements reflect BriaCell's current beliefs and are based on information currently available to management. Although the forward-looking statements contained in this news release are based upon what BriaCell believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

William V. Williams

Tel: 1-888-485-6340

(C) 2020 Electronic News Publishing, source ENP Newswire